ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,231.00
0.48%
S&P ASX All Technology
3,762.40
0.41%
Brent Oil
80.11
-0.21%
US Dollar vs AUD
1.61267
-0.16%
Bitcoin
95,639.85
1.20%
Pepperstone
Advertisement
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Germany
  5. TG

  6. Vivoryon Therapeut (05Y) Share Price

Vivoryon Therapeut

Vivoryon Therapeut (05Y)

TG
2.03
0.038
( 1.91% )
Updated: 19:48:07
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
2.03
Bid
2.00
Offer
2.025
Volume
29,363
2.005 Day's Range 2.24
0.4205 52 Week Range 9.99
Market Cap
52.916M
Previous Close
1.992
Open
2.03
Last Trade
71
@
2.0299999
Last Trade Time
19:48:07
Financial Volume
-
VWAP
-
Average Volume (3m)
41,426
Shares Outstanding
26,066,808
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
-3.62M
Net Profit
-28.34M

About Vivoryon Therapeut

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.vivoryon.com
Headquarters
Halle, Deu
Founded
-
Vivoryon Therapeut is listed in the Biological Pds,ex Diagnstics sector of the Tradegate (DE) with ticker 05Y. The last closing price for Vivoryon Therapeut was 1.99 €. Over the last year, Vivoryon Therapeut shares have traded in a share price range of 0.4205 € to 9.99 €.

Vivoryon Therapeut currently has 26,066,808 shares in issue. The market capitalisation of Vivoryon Therapeut is 51.93 € million.

Ask ADVFN Intelligence (AI)

05Y Latest News

More News

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function Vivoryon Therapeutics N.V. Presents Topline Phase...

09 December 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress...

04 December 2024
UK Regulatory

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of...

26 October 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon...

12 October 2024
UK Regulatory

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...

01 October 2024
UK Regulatory

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Vivoryon Therapeutics N.V...

12 September 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and...

06 September 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial...

05 September 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in...

18 July 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on...

09 July 2024
UK Regulatory
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.125-5.800464306292.15499992.27999991.932253162.03214404DE
40.02999991.49999529.66741.9334622.05897655DE
12-0.355-14.88469664092.38499999.66741.582414262.14844924DE
26-0.1900001-8.558563063062.229.66741.582386142.28841176DE
52-5.7800001-74.00768373887.819.990.42051001051.63388967DE
156-15.4100001-88.360092316517.4417.440.4205626341.83391855DE
260-12.5880001-86.1130120414.61822.850.4205435292.36217069DE

05Y - Frequently Asked Questions (FAQ)

What is the current Vivoryon Therapeut share price?
The current share price of Vivoryon Therapeut is 2.03 €
How many Vivoryon Therapeut shares are in issue?
Vivoryon Therapeut has 26,066,808 shares in issue
What is the market cap of Vivoryon Therapeut?
The market capitalisation of Vivoryon Therapeut is EUR 51.93M
What is the 1 year trading range for Vivoryon Therapeut share price?
Vivoryon Therapeut has traded in the range of 0.4205 € to 9.99 € during the past year
What is the reporting currency for Vivoryon Therapeut?
Vivoryon Therapeut reports financial results in EUR
What is the latest annual turnover for Vivoryon Therapeut?
The latest annual turnover of Vivoryon Therapeut is EUR -3.62M
What is the latest annual profit for Vivoryon Therapeut?
The latest annual profit of Vivoryon Therapeut is EUR -28.34M
What is the registered address of Vivoryon Therapeut?
The registered address for Vivoryon Therapeut is WEINBERGWEG 22, HALLE, 06120
What is the Vivoryon Therapeut website address?
The website address for Vivoryon Therapeut is www.vivoryon.com
Which industry sector does Vivoryon Therapeut operate in?
Vivoryon Therapeut operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
E3O1Nexoptic Technology Corp
0.024 €
(41.18%)
676
QJ4Auric Minerals Corp
1.3798 €
(31.41%)
778.67k
BR01Cruz Battery Metals Corp
0.0262 €
(30.35%)
10k
G7PAEnergy Transition Minerals Ltd
0.065 €
(27.95%)
989.2k
2BC0Panther Minerals Inc
0.035 €
(20.69%)
120k
LL3PanGenomic Health Inc
0.1096 €
(-28.37%)
3
INENIndigo Exploration Inc
0.018 €
(-25.00%)
25k
AYBAehr Test Systems Dl 01
12.50 €
(-20.13%)
1.96k
A7VAiMetal Resources Inc
0.126 €
(-16.00%)
303
PA8Paion AG
0.0202 €
(-15.83%)
7
D7GNel ASA
0.1856 €
(-5.06%)
7.8M
PF8European Lithium Limited
0.0342 €
(14.77%)
1M
G7PAEnergy Transition Minerals Ltd
0.065 €
(27.95%)
989.2k
DI6Distribuidora Internacional De Alimentacion SA
0.0171 €
(-1.16%)
860k
QJ4Auric Minerals Corp
1.3798 €
(31.41%)
778.67k

Discussion

View Full Feed
Good Sport Good Sport 5 minutes ago
This article I kept was from many years ago but states we had partnered with Pfizer...


Health Discovery Corp Hires the Dilenschneider Group
Health Discovery Corporation hires The Dilenschneider Group, a New York City IR/PR firm

SAVANNAH, Ga.- Health Disco
ABT DGX HDVY
Good Sport Good Sport 5 minutes ago
This article I kept was from many years ago but states we had partnered with Pfizer...

"HDC has also partnered with Pfizer Inc. (NYSE: PFE) for use of HDC’s SVM and SVM-RFE pattern recognition technology."


Health Discovery Corp Hires the Dilenschneider Group
ABT DGX HDVY
PROPHET-of-PROFITS PROPHET-of-PROFITS 7 minutes ago
Great posts and seeing through the noise. Rdar imo is the best place to have money in the otc right now. I have been doing this for over 24yrs. I only own ONE otc stock.

Telvantis.
RDAR
SkeBallLarry SkeBallLarry 8 minutes ago
" LOL " .. !!
Seminole Red Seminole Red 9 minutes ago
https://scontent-mia3-1.xx.fbcdn.net/v/t39.30808-6/473323273_992397186268896_4170433101098362110_n.jpg?_nc_cat=100&ccb=1-7&_nc_sid=833d8c&_nc_ohc=UebR9WKXEXsQ7kNvgELlMGV&_nc_zt=23&_nc_ht=scontent-mia3-1.xx&_nc_gid=AvB9U-Cb1bfWGguzkXzMzar&oh=00_AYDqG-tA0ScuUz90hSjz11X1LQL5aezyuhOfdBXmp9pGuQ&oe=678C04
marcis marcis 10 minutes ago
It’s beyond ridiculous now the same conjecture and half facts adding up to a pre determined statement- bearish

Then at the bottom before the debate statement -
BEARISH
What does this tell you



BEARISH
Everything that I post is just m
RDAR
PROPHET-of-PROFITS PROPHET-of-PROFITS 12 minutes ago
Telvantis / mexedia hasn't issued shares in its history on the French stock exchange. What is currently going on is all because of Jacob used rdar as an atm to support him.

Telvantis did 39m euros in h1 during a business pivot to higher margins. Ignore the noise just saying. Show pati
RDAR
biosectinvestor biosectinvestor 13 minutes ago
My understanding, and of course none of us can see behind the curtain here...

The MHRA is a collaborative regulator rather than one that seeks to be unnecessarily punitive. That is pretty much the style for the best regulators. So I agree with you on that point.

If an
NWBO
TightCoil TightCoil 16 minutes ago
From my brokerage's website:
The Bollinger Bands® are presently wider than usual, as a result of greater than normal volatility that accompanied the recent price move. Events such as this may precede a pause or reversal in the near term trend.
FNMA
marcis marcis 16 minutes ago
Agree, and Telvantis has said and is already committed in the merger, despite the doomsayers conjectures
Orlando Taddeo is a brilliant entrepreneur in the phone / tech industry
He is surrounded with seasoned brilliant people in management

“The sky is falling” crowd, t
RDAR
madcasper madcasper 20 minutes ago
hey board, I check in now and again but it is a back burner hobby now more than any other description.
mom had some stroke and she likes to watch youtube videos with closed caption on my pc during the day.
otc baby, keep at it till you can't..
CGAC
CGAC
simmons420 simmons420 21 minutes ago
Took a starter today.  Needs to break 4 with volume.  
BAER
Good Sport Good Sport 27 minutes ago
Have all of the HDC patents (regarding below subject) expired or could genomics work back in the day be tied to our Intellectual Property ?

https://www.globenewswire.com/news-release/2004/01/05/304721/2779/en/Health-Discovery-Corporation-Completes-the-Acquisition-of-Fractal-Genomics.h
HDVY
PROPHET-of-PROFITS PROPHET-of-PROFITS 31 minutes ago
We are working through the bullchit the old owner Jacob D signed off on. Telvantis didn't take out all those notes Jacob the pos did. Telvantis is cleaning up the mess.Share structure hasn't changed in over a month.

Daniel Contreras
CEO
Daniel is a multicultural financi
RDAR
Guido2 Guido2 31 minutes ago
https://x.com/guidoperei/status/1879079991562146206?s=46&t=2Y42DPZFgRdwTBHj5W8jMQ
FNMA
PROPHET-of-PROFITS PROPHET-of-PROFITS 38 minutes ago
500m shares are still to be retired. Bullish

2024 1H RESULTS REFLECT NEW STRATEGIC DIRECTION TOWARD High-margin BUSINESS
From high volume voice, low margin business. To Enterprise messaging, high-margin.
1H REVENUE € 38.7 MILLION (vs € 133.4 1H 2023)1H GROSS PROFIT MARGI
RDAR
Wolf-man jack Wolf-man jack 41 minutes ago
WQLF SAYS; Back To The Future

https://thefreshtoast.com/cbd/cbd-can-reduce-nicotine-withdrawal-symptoms-finds-new-study/

https://ir.cvsciences.com/press-releases/detail/207/cv-sciences-receives-formal-notice-of-patent-issuance-from
CVSI
Seminole Red Seminole Red 52 minutes ago
President-elect Donald Trump's second inauguration has booked a major country star to perform.

Carrie Underwood will sing "America the Beautiful" during Trump's inauguration next week, a Presidential Inaugural Committee spokesperson confirmed Monday to USA TODAY.

She wi
jeunke22 jeunke22 53 minutes ago
X, if these companies are calling to re open the discussion and it’s lightwaves material they want and they want to start their own PIC development they need to act fast to be able to be first to this huge market. No time to loose.
By the way I think Jensen Huang has an immediate issue at han
LWLG
Seminole Red Seminole Red 55 minutes ago
A University of Michigan study has concluded that it is impossible to mine enough copper to meet the push for EV transition. Not only can't it meet the copper needed for the vehicles themselves, but the power grid would be lacking as well.
"A normal Honda Accord needs about 40 pounds of coppe
LetGoodTimesRoll LetGoodTimesRoll 56 minutes ago
In an effort to put this issue to bed, NAKED SHORT SELLING of PHANTOM shares NEVER happens. NO one would waste their time selling PHANTOM shares of such a struggling company like $RNVA. 

It just doesn't make ANY sense. REAL shorts (as opposed to NAKED SHORTS) would have their guns poi
RNVA

Your Recent History

TG
05Y
Vivoryon Therapeut
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads